ArQule has built a proprietary library containing tens of thousands of small molecules designed for certain types of kinase inhibitors having drug-like properties. Through a combination of biophysical and biochemical screens against many kinases, we have identified several chemical series which have advanced through lead optimization against targets such as BTK, mutant BTK, TAK1, ACK1 and other targets. We have identified chemical series that have advanced through the hit-to-lead stage for targets such as S6K, CDK8 and TNIK.
Additionally, we are leveraging this proprietary compound collection beyond kinases and have identified targets in the field of immuno-oncology. We believe that chemical scaffolds present in our library may have a high potential of generating hits amenable to optimization in this area.